Read the original here:
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19...

Go here to read the rest:
Silence Therapeutics plc Announces $45 Million Private Placement

Read the original:
Orchard Therapeutics Announces $150 Million Strategic Financing

Read more:
IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Read the rest here:
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Continued here:
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

See original here:
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

Originally posted here:
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Read more:
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

See the original post:
GBT Announces New Employment Inducement Grants

Continued here:
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

Originally posted here:
Bespoke Extracts Welcomes Trend Expert Carly Stojsic as New Director of Marketing

Originally posted here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 3-4 February 2021

Continue reading here:
Bright Minds Biosciences Announces Listing on Canadian Stock Exchange

Read this article:
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

View post:
Valneva - Déclaration d’actions et de droits de vote – Janvier 2021

Excerpt from:
Amendment: Trading by management and close relations of management

Read more:
argenx announces closing of global offering

Continue reading here:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more from the original source:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)